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Abstract
Myelofibrosis in association with autoimmune disorders has been consistently recognized in sporadic case reports over a 
number of years. Autoimmune myelofibrosis has been described most commonly in association with systemic lupus ery-
thematosus (SLE). In addition, myelofibrosis presenting as cytopenias and showing clinical response to immunosuppres-
sant drugs, notably steroids, has been reported with a wide range of immune-mediated disorders, including Sjögren’s 
syndrome, polyarteritis nodosa, rheumatoid arthritis, ulcerative colitis, and primary biliary cirrhosis. Attempts have been 
made to define a syndrome of primary autoimmune myelofibrosis (PAIMF), as a distinct steroid-responsive clinicopatho-
logic entity with excellent prognosis. Herein, we describe three cases of autoimmune myelofibrosis with a review of the 
literature. (Turk J Hematol 2009; 26: 146-50)
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Özet
Otoimmün bozukluklar ile ilişkili miyelofibrozis birkaç yıldan bu yana, sürekli olarak sporadik olgu sunumlarında göze 
çarpmaktadır. Otoimmün miyelofibrozis en yaygın olarak sistemik lupus eritematozus (SLE) ile ilişkili olarak tanımlanmaktadır. 
Ayrıca, sitopeni ile kendini gösteren ve immün sistemi baskılayan ilaçlara, özellikle steroidlere, klinik yanıt oluşturan miyelo-
fibrozis çok sayıda immun-aracılı bozuklukla beraber bildirilmektedir. Bunlar Sjögren sendromu, poliarteritis nodosa, roma-
toid artrit, ülseratif kolit ve primer biliyer sirozu içermektedir. Çok iyi bir prognoza sahip, steroide yanıt veren farklı bir 
klinikopatolojik antite olarak primer otoimmün miyelofibrozis (POIMF) sendromunu tanımlama girişimlerinde bulunulmuştur. 
Biz, burada literatürü gözden geçirerek, üç otoimmün miyelofibrozis olgusunu tanımlamaktayız.
(Turk J Hematol 2009; 26: 146-50)
Anahtar kelimeler: Miyelofibrozis, otoimmün, lökoeritroblastozis, splenomegali, otoantikorlar
Geliş tarihi: 21 Eylül 2007  Kabul tarihi: 11 Eylül 2008Introduction
Bone marrow fibrosis can arise as a result of a wide range 
of neoplastic and non-neoplastic disorders [1]. Whereas infec-
tion, metastasis and primary hematological malignancy are 
more frequently causative, systemic lupus erythematosus 
(SLE) is perhaps the disease that has been implicated earliest 
and most frequently in cases of myelofibrosis associated with 
autoimmune disorders. Reports in the literature [2,3] character-
ize primary autoimmune myelofibrosis (PAIMF) on the basis of 
a lack of an association with a well-defined autoimmune disor-
der. There may be positive serology for autoantibodies with 
variable cytopenias. Absence of splenomegaly, minimal tear-
drop poikilocytosis and leukoerythroblastosis in the peripheral 
blood are characteristic. The condition responds clinically to 
steroids, with improvement in cytopenias. Apart from SLE, 
myelofibrosis has been reported in several cases with estab-
lished systemic immune disorders like juvenile rheumatoid 
arthritis [4], ulcerative colitis [5], primary biliary cirrhosis [6], and 
idiopathic thrombocytopenic purpura [7]. However, immuno-
logical abnormalities have also been reported in idiopathic 
myelofibrosis in the form of circulating immune complexes, 
positive serological tests like antinuclear antibodies (ANA), low 
complement levels, bone marrow lymphoid nodules, and 
therapeutic response to steroids [8-14]. 
           
Materials and Methods
Herein we present the clinico-hematological profile of three 
cases fitting the diagnosis of PAIMF amongst a total of 118 
cases of myelofibrosis diagnosed within the last three years. 
The clinico-hematological characteristics of the cases are sum-
marized in Table 1. An analysis of 10 case reports of AIMF 
reported in the literature is presented in Table 2.
Case 1 
This 38-year-old male presented with weakness of two 
years’ duration. On examination, he had pallor and hepato-
splenomegaly. There was no lymphadenopathy, fever or 
bleeding manifestations. Peripheral blood examination revealed 
hemoglobin (Hb) 52 g/L, total leukocyte count (TLC) 3.2 x109/L 
and platelet count 126 x109/L. Peripheral blood smear showed 
normocytic, normochromic red blood cells (RBCs) and no tear-
drop poikilocytes or nucleated RBCs. There were no abnormal 
white blood cells (WBCs). Platelets were mildly reduced. The 
bone marrow trephine biopsy was hypercellular with 100% cel-
lularity and no increase or clustering of megakaryocytes. 
However, dysplastic megakaryocytes with hypolobated nuclei 
and bare megakaryocyte nuclei were present (Figure 1). 
Intrasinusoidal hematopoiesis was absent. There was a mod-
erate diffuse infiltrate of mature lymphocytes. Reticulin was 
Grade 2. The patient was treated with Inj methylprednisolone 
followed by oral prednisolone. At five months, his blood counts 
were normal. Spleen size regressed to 2 cm below the left 
costal margin.
Case 2  
This 29-year-old male presented with generalized weak-
ness of three months’ duration. At presentation, he was pale 
but had no organomegaly, lymphadenopathy or bleeding. 
Peripheral blood examination revealed Hb 73 g/L, TLC 7.3 
x109/L and platelets 162x109/L. His anemia progressed to Hb 
68 g/L after two weeks, at which time the spleen became pal-
pable up to 4 cm below the left costal margin. Peripheral blood 
smear showed predominantly normocytic, normochromic 
RBCs with small numbers of teardrop poikilocytes and nucle-
ated RBCs. There were no abnormal WBCs. Platelets were 
adequate. Bone marrow trephine biopsy was normocellular 
with 40% marrow cellularity, consisting of a patchy distribution 
of myeloid and erythroid cells and normal numbers of non-
clustered megakaryocytes, some of which had hypolobated 
nuclei. Scattered interstitial lymphocytes and focal non-para-
trabecular aggregates of mature lymphocytes were present 
(Figure 2). There was no intrasinusoidal hematopoiesis. 
Reticulin was Grade 2. The patient was treated with Inj meth-
ylprednisolone and oral steroids. At one year of follow-up, his 
spleen remained palpable 2 cm below the left costal margin 
although blood counts were normal.
Case 3 
This 33-year-old male presented with generalized weak-
ness and low-grade fever of three years’ duration. On exami-
nation, he had pallor, splenomegaly 3 cm below the left costal 
margin, and no lymphadenopathy or bleeding manifestations. 
Computerized tomography (CT) scan of the abdomen revealed 
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Table 1. Clinico-hematological characteristics of the three cases of primary autoimmune myelofibrosis in this report 
Case    Age/  Associate  Spleen  Hb g/L  TLC  Platelet  Serology  Response to  Bone
No     Sex  d Disease   (below LCM)   x109/L Count  x109/L   Steroids  Marrow  Histology
1   38/M  None  4  cm  52  3.2  126  ANA+,  PR  Reticulin
                Anti ds    Grade 2
               DNA+
2   29/M  None  4  cm  68  7.3  162  ANA-,  PR  Reticulin
                Anti ds    Grade 2
                 DNA-, RF-
3   33/M  None  3  cm  59  2.9  95  DCT+  PR  Reticulin 
               ANA-,    Grade  3
               Anti  ds
               DNA-
LCM: Lower left costal margin; ANA: Antinuclear antibody; RF: Rheumatoid factor; PR: Partial remission (normal blood counts, still palpable spleen); DCT: Direct Coombs’ 
test; -: Negative; +: Positivea paravertebral mass. Fine needle aspiration cytology (FNAC) 
of the mass revealed extramedullary hematopoiesis. Peripheral 
blood examination revealed Hb 59 g/L, TLC 2.9 x109/L and 
platelets 95 x109/L. Peripheral blood smear showed predomi-
nantly normocytic, normochromic, red cells, no nucleated 
RBCs and small numbers of teardrop poikilocytes. There were 
no abnormal WBCs and platelets were moderately reduced. 
Bone marrow biopsy was hypocellular (marrow cellularity of 
10%). Clustered megakaryocytes with hypolobated forms and 
naked megakaryocyte nuclei were present. Myeloid and ery-
throid cells were reduced. Focal non-paratrabecular aggre-
gates of mature lymphocytes were present. There was no 
intrasinusoidal hematopoiesis. Reticulin was Grade 3 (Figure 
3). The patient was treated with oral steroids. At one year of 
follow-up, his blood counts were normal and the paravertebral 
mass had regressed, but the spleen remained palpable 2 cm 
below the costal margin.
Discussion 
 In a survey of the literature dating back to 1969, Rizzi et al. 
[2] discovered 24 case reports of AIMF. They found 17 cases 
associated with SLE, and the rest with diverse diseases like 
Sjögren’s syndrome, Hashimoto’s thyroiditis, autoimmune 
hemolytic anemia, psoriasis, and synovitis and cases with iso-
lated positive ANA test.
 Pullarkat et al. [15] defined a syndrome of PAIMF, high-
lighting the features of a lack of association with a well-defined 
autoimmune syndrome, no splenomegaly, presence of autoan-
tibodies and the absence of a disorder known to cause myelo-
fibrosis. They emphasized lack of teardrop poikilocytes and 
leukoerythroblastosis in the peripheral blood with absence of 
clustered and atypical megakaryocytes and the presence of 
lymphoid infiltrates in the bone marrow in addition to fibrosis. 
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Figure 1. Bone marrow biopsy of Case 1 showing presence of dysplastic mega-
karyocytes with hypolobation and naked megakaryocytic nuclei. There is diffuse 
increase in mature lymphocytes (hematoxylin and eosin, x400)
Table 2. Clinico-hematological characteristics of 10 cases of primary autoimmune myelofibrosis reported in the literature referans
Case  Age  Associated Disease  Spleen  Hb g/L  TLC  Platelet  Serology  Response to
no   /Sex        x109/L Countx109/L   Steroids
1  73/M  Psoriasis, Kaposi’s sarcoma  No  Anemia  NM  R  DCT+  CR
2  48/F  Diabetes mellitus, AIHA  No  Anemia  R  NM  DCT+  CR
3 40/F  Synovitis  No  Anemia  R  R  ANA+ CR
4 42/M  None  No  Anemia  R  R  ANA+  CR
5 22/M  None  No  Anemia  NM  NM  DCT+,  ANA+  PR
6  47/F  Diabetes mellitus, Thyroiditis, AIHA  No  Anemia  NM  R  NM  CR
7 68/F Autoimmune  hepatitis  No  Anemia  R  R  ANA+, CR
             DCT+ 
8 72/F  Sjögren’s  syndrome No  115  1.3  206  RF+  CR
9 43/F  None  No  79  7.8  16 AntiNuM  CR
            A+
10  59/F  Sjögren’s syndrome  No  122  2.38  246  RF+,    NR
             ANA+,
             anti-SSA+
NM: Not mentioned; RF: Rheumatoid factor; ANA: Antinuclear antibody; DCT: Direct Coombs’ test; CR: Complete response; PR: Partial response; NR: No response;
 R: reduced; -: Negative; +: Positive 
Figure 2. Bone marrow biopsy of Case 2 with non-clustered megakaryocytes, 
few with hypolobated nuclei and a scattered interstitial lymphocyte infiltrate with 
focal non-paratrabecular aggregates (hematoxylin and eosin, x400)Bass et al. [16] similarly described rare or absent teardrop 
poikilocytes and nucleated RBCs in the peripheral blood 
smear. Their cases showed megakaryocytic dysplasia without 
clustering, lymphoid infiltrates and intrasinusoidal hematopoi-
esis. One case had autoimmune hemolytic anemia and spleno-
megaly at presentation. 
 Paquette et al. [3] defined AIMF as an uncommon disorder 
with anemia and thrombocytopenia with either limited clinical 
manifestations of an autoimmune disease or exacerbation of 
previously established SLE. They opined that absence of sple-
nomegaly in myelofibrosis may suggest an autoimmune disor-
der and that tests for LE cell and ANA are invariably positive in 
such cases. 
As is evident from our cases (Table 3), the hematological 
features of AIMF described in the literature also show some 
overlapping and some distinct features from chronic idiopathic 
myelofibrosis (CIMF). In the detailed analysis of 24 cases of 
AIMF, hypocellular marrows were found in half the cases, 
hypercellular marrow in 10 cases and normocellular marrow in 
two cases [2]. Reticulin fibrosis ranged from 2+ to 4+, and 
none of the cases had clustered megakaryocytes in the mar-
row. Two cases had lymphoid infiltration in the marrow. All 
cases showed absence of significant leukoerythroblastosis and 
teardrop poikilocytosis in the peripheral blood smears and lack 
of organomegaly.
 Bass et al. [16] in their cases found rare to moderate num-
bers of teardrop cells, rare nucleated RBCs with moderately 
reduced to normal platelet counts, mild to moderate anemia, 
and normal to mild reduction in the leukocyte counts. The bone 
marrow examination showed grade 3+ to 4+ reticulin fibrosis, 
cellularity ranging from 30% to 100% and non-clustered mega-
karyocytes. Erythroid hyperplasia and megakaryocyte abnor-
malities in the form of small size with hypolobated and hyper-
chromatic nuclei were present. The notable feature of intra-
sinusoidal myeloid, erythroid precursors and megakaryocytes 
was present in all three cases. Interstitial lymphoid infiltrates 
with non-paratrabecular polyclonal aggregates were present in 
the three cases.
An analysis of the 10 cases reported in the literature [2,15] 
(Table 2) reveals the association of a well-defined autoimmune 
disorder in 7/10 cases. This association was absent in our 
cases, although positive tests for auto-antibodies were present 
in two cases (Cases 1 and 3). Although Case 1 had ANA and 
anti-ds DNA positivity (immunologic disorder) along with hema-
tologic disorder, other clinical manifestations to fulfil the criteria 
for SLE [17] were lacking. Similarly, Case 3 had direct Coombs’ 
test positivity. However, no spherocytes or nucleated RBCs 
were seen in the peripheral smear; rather, a few teardrop cells 
were present. Bone marrow showed significant fibrosis and 
focal aggregates of mature lymphocytes. Thus, both cases fit 
the diagnosis of PAIMF, which was reinforced by their steroid 
responsiveness.
Splenomegaly was present in all our cases in contrast to 
what is reported in most of the cases in the literature. Peripheral 
blood examination revealed lack of prominent teardrop poikilo-
cytosis and nucleated RBCs. All the cases had cytopenias. In 
addition to bone marrow fibrosis, megakaryocytic dysplasia 
was present in all cases, with clustered megakaryocytes in 
Case 3 (with extramedullary hematopoiesis). Bone marrow 
lymphoid infiltrates were present in all cases, mostly diffuse but 
also focal and non-paratrabecular. None of our cases had 
intrasinusoidal hematopoiesis in the bone marrow.
Treatment with steroids resulted in complete response in 
8/10 cases [2,15] (Table 2). Complete response was defined 
as normalization of blood counts. Repeat bone marrow biop-
sies in 3/10 cases revealed only partial resolution of the fibrosis 
in one case after four months of therapy. Similarly, our cases 
showed normal blood counts following steroid therapy, at 
intervals ranging from five months to one year. There was only 
partial regression of splenomegaly. Bone marrow biopsies, 
however, were not repeated. Although some features overlap-
ping with CIMF were present in our cases, the steroid respon-
siveness manifested in normalization of blood counts and 
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Table 3. Comparison of salient features of CIMF and PAIMF 
Features  CIMF  Primary AIMF   Primary 
AIMF   (literature)  (our  cases)
Pancytopenia +/-  +  +
Teardrop cells  ++  +/-  +/-
Leukoerythroblastosis ++  +/-  _
Splenomegaly present  absent  present
Bone marrow fibrosis  present  present  present
Clustered megakaryocytes  ++  +/-  1 of 3
Dysplastic megakaryocytes  +/-  +/-  2 of 3
Lymphoid infiltrate  +/-  ++  all cases
Intrasinusoidal hematopoiesis  +/-  +/-  none
Clonal cytogenetic abnormality +/-  no study  not done
Association with autoimmune  -  +/-  -
disease
Autoantibodies  +/-  +.  2 of 3
Response to steroids  no study  present  all cases
Figure 3. Bone marrow biopsy of Case 3 showing marked diffuse reticulin fibro-
sis (reticulin staining, x400)partial regression of splenomegaly is the unifying feature in all 
three cases that strongly favors the diagnosis of AIMF. As there 
was lack of a well-defined autoimmune disorder in these 
cases, they fit the diagnosis of PAIMF.
Bone marrow histology in at least one case (Case 3) 
showed some features resembling idiopathic myelofibrosis, in 
the form of clustered megakaryocytes and fibrosis. This case 
also had extramedullary hematopoiesis. Lymphoid infiltrates 
and autoimmune phenomenon have been reported in idio-
pathic myelofibrosis [8-13]. An analysis of clinical characteris-
tics of these cases reveals that lymphoid nodules in the bone 
marrow in idiopathic myelofibrosis correlates with less-
advanced disease, with smaller spleen size and lower WBC 
and platelet counts. Bone marrow biopsies with lymphoid nod-
ules in cases of idiopathic myelofibrosis are more cellular and 
show less fibrosis [13]. However, presence of peripheral blood 
features of prominent teardrop poikilocytosis and nucleated 
RBCs, clonal cytogenetic abnormalities and lack of steroid 
responsiveness may serve to distinguish idiopathic myelofibro-
sis with autoimmune features from AIMF. In Table 3, we pres-
ent a comparison between the salient features of CIMF and 
PAIMF reported in the literature and those revealed in our 
cases.
In conclusion, PAIMF is an uncommon entity, which needs 
to be diagnosed correctly since a specific treatment option is 
available. The definition of primary AIMF must necessarily 
include lack of association of a well-defined autoimmune disor-
der. Splenomegaly may or may not be present. Presence of 
splenomegaly should not negate the diagnosis as is evident 
from our cases. Lack of or minimal teardrop poikilocytes and 
nucleated RBCs in the peripheral blood together with fibrosis 
and lymphoid infiltrates in the bone marrow, positive tests for 
auto-antibodies and steroid responsiveness should be pres-
ent. Diagnostic criteria may also include lack of clonal cytoge-
netic abnormalities. There should be documented regression 
of bone marrow fibrosis on steroid or other immunosuppres-
sive therapy in the long term.
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